Illumina’s Alliance for Genomic Discovery added pharmaceutical partners as the project continues to amass hundreds of thousands of sequenced genomes linked to clinical records, drawing interest from target‑discovery and real‑world‑data teams. Companies such as Alnylam joined the AGD to exploit large sample sets and phenotype links for target validation. Separately, the Long Life Family Study selected PacBio HiFi long‑read sequencing (Revio) to generate comprehensive genomes and methylation data across thousands of pedigreed participants. Long‑read, methylation‑aware data will enable detection of structural variants, repeat expansions and epigenetic markers tied to exceptional longevity. Together these moves highlight growing industry investment in richer genomic datasets for target discovery and translational programs.